OCUPHIRE PHARMA INC. - COMMON STOCK
1.2900
27-九月-24 15:59:54
15 分钟延时
股票
-0.0100
-0.77%
今日范围
1.2502 - 1.3050
ISIN
N/A
来源
NASDAQ
-
08 3月 2022 08:00:02 条件 Nasdaq GlobeNewswire
-
08 2月 2022 08:00:02 条件 Nasdaq GlobeNewswire
-
31 1月 2022 06:00:00 条件 Nasdaq GlobeNewswire
-
Ocuphire to Host Virtual Investor R&D Day on January 31st
25 1月 2022 07:00:01 条件 Nasdaq GlobeNewswire
-
05 1月 2022 07:00:01 条件 Nasdaq GlobeNewswire
-
08 12月 2021 08:00:01 条件 Nasdaq GlobeNewswire
-
23 11月 2021 09:00:01 条件 Nasdaq GlobeNewswire
-
Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update
12 11月 2021 07:00:02 条件 Nasdaq GlobeNewswire
-
01 11月 2021 09:30:31 条件 Nasdaq GlobeNewswire
-
07 10月 2021 07:00:01 条件 Nasdaq GlobeNewswire
-
01 10月 2021 08:49:48 条件 Nasdaq GlobeNewswire
-
Ocuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall
27 9月 2021 07:00:00 条件 Nasdaq GlobeNewswire
-
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 9月 2021 17:00:00 条件 Nasdaq GlobeNewswire
-
Ocuphire Pharma Presenting at Four Conferences in September
02 9月 2021 07:00:02 条件 Nasdaq GlobeNewswire
-
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
12 8月 2021 07:00:01 条件 Nasdaq GlobeNewswire
-
Ocuphire Pharma Presenting at Two Conferences in August
06 8月 2021 07:30:00 条件 Nasdaq GlobeNewswire
-
22 7月 2021 08:00:02 条件 Nasdaq GlobeNewswire
-
Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July
13 7月 2021 09:00:01 条件 Nasdaq GlobeNewswire
-
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09 7月 2021 17:00:00 条件 Nasdaq GlobeNewswire
-
Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints
30 6月 2021 07:15:00 条件 Nasdaq GlobeNewswire